| Serial Number | 98318688 |
| Word Mark | NXERA |
| Filing Date | Monday, December 18, 2023 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Saturday, March 1, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical preparations for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders; Medicines for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders; biological products for medical purposes, namely, G-protein coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, transmembrane proteins and parts thereof both being for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the fields of chemical and biological drug discovery, lead identification, diagnostics and therapeutic purposes; biological and chemical products for medical use, namely, protein supplements, G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, transmembrane proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, G-proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, antibodies for medical purposes, and synthetic peptides and parts thereof being synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders; chemical reagents for medical use, and protein for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders and parts thereof for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the field of medical diagnostics; biological products for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the fields of chemical and biological drug discovery, lead identification and diagnostics; biological products for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for therapeutic purposes; biological formulation for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the field of developing chemical and biological pharmaceutical products; biological formulation for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the field of identifying lead chemical and biological products; biological formulation for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for diagnostic use; biological formulation for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for therapeutic use; proteins and G-protein-coupled receptors, both for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders for use in the field of drug discovery purposes; biological reagents for medical purposes and small chemical entities for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, transmembrane proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, G-proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, antibodies for medical purposes, and synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders; proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, G-protein-coupled receptors for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, transmembrane proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, G-proteins for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders, antibodies for medical purposes, and synthetic peptides for use in medical diagnostics for modulating G-protein-coupled receptors, transmembrane proteins and parts thereof for treating and preventing GPCR-mediated or GPCR-implicated diseases and disorders. |
| Goods and Services | Business management, business organization consulting, and business administration, all provided in the fields of chemical products, biological products, pharmaceuticals, design and development of drugs, and drug discovery; Business management, business organization consulting, and business administration, all provided in the field of pharmaceutical and biopharmaceutical research and development, and field of technologies related to proteins and G-protein-coupled receptors; wholesale and retail store services featuring pharmaceuticals, biological products and chemical and biological preparations. |
| Goods and Services | Chemical products and proteins both for use in the manufacture of industrial chemicals and biological pharmaceutical products; chemical products being industrial chemicals and protein in raw material form for scientific and medical research being research of chemical and biological pharmaceutical products; chemical products being industrial chemicals and proteins for industrial use in the field of diagnostic use, except medical or veterinary uses; protein for industrial use and G-protein coupled receptors being protein for industrial use for manufacturing pharmaceutical products; protein for industrial use and G-protein-coupled receptors being protein for industrial use for the research of pharmaceutical products; industrial chemicals and protein for industrial use for use in the fields of chemical and biological drug discovery, lead identification and diagnostics; protein for industrial use and G-protein-coupled receptors being protein for industrial use for drug discovery purposes; industrial chemicals and biologicals in the nature of protein for industrial use, transmembrane proteins and G-proteins both being protein for industrial use, G-protein-coupled receptors being protein for industrial use, and fragments thereof being sequences of amino acids in the nature of amino acids, other than for medical or veterinary purposes, for use in the fields of chemical and biological drug discovery, lead identification and diagnostics; protein for industrial use in the nature of transmembrane proteins and G-proteins both being protein for industrial use, G-protein-coupled receptors being protein for industrial use, and fragments thereof being sequences of amino acids in the nature of amino acids, other than for medical or veterinary purposes, for use in the fields of pharmaceutical research and drug discovery purposes. |
| Goods and Services | Pharmaceutical compounding services; pharmaceutical advice and medical and pharmaceutical consultation; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical and pharmaceutical consultation in the fields of research, creation, development and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid services provided in the field of drug discovery and field of use of G-protein- coupled receptors in the design and development of pharmaceutical products; |
| Goods and Services | Drug discovery services and pharmaceutical discovery services being pharmaceutical research services; Biotechnology research; pharmaceutical research services; chemical and medical testing in the nature of testing of chemicals; research, development, advice, consultancy and information services, namely, design and testing of new products for others; research and development services in the field of pharmaceutical preparations being pharmaceuticals and biopharmaceuticals and field of pharmaceutical preparations being technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in the fields of chemical and biological drug discovery and development; pharmaceutical research services and pharmaceutical products development for identifying lead chemical compounds; examination and research services being pharmaceutical research services in the field of medicinal and synthetic chemistry; scientific research and development services in the fields of creation of libraries and collections of biologicals, chemicals and compounds; research, creation, and development, namely, scientific research and development in the field of chemical and biological drug targets for screening purposes; research, analysis and examination, namely, scientific research and development in the field of identification of compounds through automated screening processes; scientific research and development services in the field of chemical and biological pharmaceutical development; medical research laboratory services; provision of information, advisory services and consultancy in connection with all of the aforesaid services; |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | NXERA PHARMA CO., LTD |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 99 - Other |
| Address | TOKYO 107-0052 JP |
| Party Name | Sosei Group Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Tokyo 102-0083 JP |
| Event Date | Event Description |
| Monday, December 18, 2023 | NEW APPLICATION ENTERED |
| Monday, March 25, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, July 4, 2024 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, July 16, 2024 | ASSIGNED TO EXAMINER |
| Monday, December 2, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, December 2, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, December 2, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, December 12, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, February 28, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 28, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, March 1, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 12, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, December 12, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |